Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$33.61 USD
-1.20 (-3.45%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $33.62 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Biohaven Ltd. [BHVN]
Reports for Purchase
Showing records 101 - 120 ( 268 total )
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Don''t Call It A Comeback - Pre-Announces Third Nurtec ODT Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Another Quarter, Another Nurtec Revenue Beat; Reiterate Buy, Raise Price Target to $135
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 6/4/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker - Week Ending 5/28/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker - Week Ending 5/21/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
FDA Approves Nurtec in Preventative Migraine, Dissolving the Line Between Acute and Preventive Treatment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
One-Two Punch With Prevention Label Expansion For Nurtec ODT
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Biotechnology - Neurology Prescription Sales Tracker -- Week Ending 5/7/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Lots to Look Forward to for Biohaven Starting with 2Q; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D